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ABSTRACT
The causative agent of malignant tertian malaria, Plasmodium falciparum undergoes an
arrested growth phenotype of its erythrocytic stage when under drug-stress. Recent artemisinin
treatment failures seem to be indicative of such induction followed by recrudescence rather than
actual therapeutic failure. Likewise, P. vivax hypnozoites are the prototypic dormants and the
latent infections for which they are responsible prove most difficult to treat. Dihydroartemisinin,
an artemisinin-derivative, can be used to exploit this mechanism by inducing a dormant state in
ring-stage P. falciparum parasites and in turn, their recovery may be used as a screening period
for compounds that inhibit or foster growth.
Specifically, parasites stably transfected with luciferase were used to quantitatively
observe growth (or lack thereof) response of parasites to the phytohormone gibberellic acid and
the herbicide, fluridone. Using their behavior as comparative controls, the Medicines for Malaria
Venture (MMV) Malaria Box was screened for similar activity. The most active compound,
1,2,3,4-tetrahydroacridin-9-ol a quinoline-derivate caused cells to wake even earlier than
expected. Since quinine and other such drugs have historically been most effective in treating
malaria, it seems appropriate that such a finding was made. Following this the MMV Box was
screened again against uninduced 3D7 parasites to determine if any were capable of causing a
dormant response under the hypothesis that such a reaction is a defensive adaptation of P.
falciparum.
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Four compounds were found to be active of which two appear to be inducing dormancy
in the second cycle rather than the first akin to DHA. These quiescent periods also appear to be
shorter indicating that the latter is more efficient. It is possible that given the length of interaction
with artemisinin, P. falciparum is more adept to respond to its derivatives likewise the
mechanism of action may be different enough to change the nature of the response.
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INTRODUCTION
Plasmodium
As an obligate intracellular parasite, the apicomplexan Plasmodium falciparum is one of
the causative agents of malaria. It is not the only cause however, as this disease may be initiated
by five additional species including P. vivax, P. knowlesi, P. malariae, P. ovale and most
recently discovered, P. cyanomolgi. Its definitive host is its mosquito vector whereas humans
serve as both reservoir and intermediate host. The disease, for which it is responsible, is thus a
result of its journey through a fairly elaborate life cycle (White et al., 2014).

Malaria Epidemiology
An ancient disease, malaria can trace its origins to medieval Italian as mal aria or simply
‘bad air’ in reference to an area of Rome known as the Pontina which was in turn characterized
by its surrounding swamp and as one would expect, high rates of malaria transmission (Beltz,
2011). To date, it continues to be one of the most prevalent parasitic infections of critical need
for sustained attention. According to the World Health Organization, on a global scale 3.4 billion
people may be considered at risk. In 2012 they estimated 207 million cases resulted 627,000
deaths with more than 85% of these cases and 90% of the deaths occurring on the African
continent (WHO, 2013). Of note is the fact that although a majority of individuals may be
parasitized at any given time, only a minority will experience severe symptoms. This is
especially true in areas of high endemicity where repeat exposure results in some development of
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natural immunity. In this way, such places see malaria as more of an issue of morbidity rather
than mortality. Furthermore, these nations are left at a stark economic disadvantage due to an ill
workforce, as well as lack of tourism and company investments and the educational loss future
generations may incur effectively keeping their society underdeveloped (Marsh & Snow, 1997)
(Lopez Del Prado et al., 2014).

Life Cycle
The life cycle may be divided into two forms – sexual reproduction/sporogony, which
occurs in the mosquito, and asexual reproduction/schizogony, which occurs in the human. A
human may only gain infection through the bite of an infected Anopheles mosquito specifically
through the entry of sporozoites into the wound, as she takes a blood meal. Sporozoites are
motile and travel from the dermis to the parenchyma of the liver within the first 15 minutes to a
few hours, where they infect hepatocytes. Over 2 – 7 days, the sporozoites develop/differentiate
turning the infected liver cell into a schizont, which in turn bursts releasing on average 10,000 –
30,000 merozoites (White et al., 2014). These are motile as well and travel to the bloodstream to
infect erythrocytes. Blood stage parasites follow a cycle of invasion, growth, and emergence by
red blood cell (RBC) lysis that takes 48 hours for P. falciparum, P. vivax, and P. ovale, 72 hours
for P. malariae, and 24 hours for P. knowlesi. It is this cyclic release that causes malarial
pathology (White et al., 2014).
Rather than continuing with this sequence, some merozoites instead commit to
differentiate into gametocytes, a gamete precursor. Development is divided into 5
morphologically distinct stages with the final circulating in the peripheral blood until it is picked
up by another Anopheles mosquito to continue transmission. Within the mosquito, the macro-
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and microgametocytes combine to form a zygote. This zygote passes through the insect’s midgut
via yet another motile stage, the ookinete, before encysting on the outside of the gut as an oocyst.
The latter subsequently bursts and release sporozoites, which travel to the salivary gland to
render the host vector competent in passing infection forward.
A distinctive feature that distinguishes P. falciparum from P. vivax/P. ovale malaria is the
presence of a latent liver form in the latter (Markus, 2011). Hypnozoites are a dormant stage that
may persist for weeks or even years in affected individuals. Elimination is therefore much more
difficult as will be discussed in greater detail subsequently.

Disease Signs & Symptoms
Malaria manifests itself most distinctively in the marked paroxysms attributed to the
cyclic lysis of infected RBCs (Heymann, 2008). Symptoms may include fever/chills, nausea,
headache, fatigue and mild anemia at this initial stage. It is a recommendation of the WHO that
any individual in an endemic area presenting with fever be screened through microscopy or a
rapid diagnostic test where available. Real-time polymerase chain reaction (qPCR) remains the
gold standard but may not be available in many regions. Microscopy can be just as effective
though it would be necessary to take repeat samples over 12 to 24 hours as the parasitemia may
vary depending on which point of the life cycle the protozoan is in. An undetected and likewise
untreated infection of P. falciparum malaria can have severe complications such as enlargement
of the spleen and/or liver, often presented with jaundice in children (Heymann, 2008). Age
seems to be a determining factor regarding which symptoms manifest. Adults may experience
pulmonary edema and kidney injury while children may more commonly see severe anemia, and
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hypoglycemia. Across all age groups, coma as a result of cerebral malaria can occur contributing
to over 1 million malaria deaths every year.
The pathogenesis of this complication is not exactly understood. Mechanistically, it
seems to involve microvascular sequestration by infected red blood cells (RBCs), overproduction
of pro-inflammatory cytokines and dysfunctional coagulation (Mohanty et al., 2014). A known
method of immune evasion, cytoadherence allows parasites to remain undetected by binding to
endothelial tissue through modified RBC surface ligands. It is the reason that peripheral blood
samples are only able to detect the earliest parasite stages and why screening must be done over
a period of 24 hours. As the infection progresses, erythrocytes adhere to each other in a process
called rosetting as well as to the lining of tissues, most detrimentally that of blood vessels
(Wright, 2014). If this sequestration occurs in the brain, blood flow may be obstructed leading to
symptoms like ataxia, swelling/edema and hemorrhage all of which contribute to the patient
falling into a malaria-induced coma. There appears to be evidence that upregulation of
proinflammatory cytokines like tumor necrotic factors (TNF) and interferon-γ (INF-γ) at this site
correlates with higher levels of parasite density. Cerebral malaria is survivable though not
without some consequences, 3 – 15% of children incur permanent neurological damage like
cortical blindness, cerebral palsy, deafness, and learning impairments (Ioannidis, Nie, & Hansen,
2014).

Prevention & Treatment
The best course of action regarding treatment is thus early detection with the screening
and diagnostic methods already described being applied to at-risk populations. Hence control
methods can be aimed at three distinct groups: patients, the exposed and the mosquito vector
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itself (Hafalla, Silvie, & Matuschewski, 2011). The latter two may be the most essential. Curbing
mosquito populations through source reduction of their habitats, draining and clearing of
breeding areas has had some effect in decreasing incidence. However, indiscriminate control
programs are hardly cost-effective and the Anopheles mosquito is highly anthropophilic;
consequently an appropriate strategy would need to target it indoors and out (Beier et al., 2008).
In other words, the management of the vector needs to be integrated with the needs of the
community and the ecological circumstances of the area. The use of long-lasting insecticide
treated bed nets can reduce incidence by 50% in high-transmission areas and 62% in those of low
(Ulrich et al., 2013). Likewise, indoor residual spraying has shown to be similarly effective if
combined with robust surveillance to ensure that control correlates to risk. Several compounds
have environmental implications and it is imperative that they be used with care. It should be
noted that the goal of vector control is not annihilation of the insect population but rather the
sufficient reduction of malaria transmission in an effort to reduce the entomological inoculation
rate. This is the case for most temperate countries, the US included, where the mosquito lives on
but the malarial parasite is no longer endemic.
In terms of preventative treatment, malarial prophylaxis may be suppressive or causal
with the primary distinction being the former affects blood stage infections only while the latter
can affect parasites in both the liver and blood (Lopez Del Prado et al., 2014). Some examples of
suppressive prophylaxis include doxycycline, mefloquine and chloroquine while causal
prophylaxis may be drugs like malarone and primaquine. Chloroquine is typically used in the
treatment of non-falciparum malaria as resistance has been spreading especially in endemic areas
with previously high use. The specific regimen used and its dosage depends on the individual
taking said medication and the region to which they travel (Lopez Del Prado et al., 2014).
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Mechanisms of action vary but all in some manner interfere with an essential functional
component of the cell be it in terms of metabolism or replication. To start, the tetracyclines
interfere with apicoplast replication. The quinolones disrupt hemoglobin digestion allowing
heme to accumulate to toxic levels as a waste product. Malarone consists of two compounds
atovaquone and proguanil hydrochloride, and together they obstruct pyrimidine biosynthesis and
thereby DNA replication (Flannery, Chatterjee, & Winzeler, 2013). Lastly primaquine has been
shown to inhibit the proper formation of transport vesicles and severely disrupt function of
mitochondria. It is important in treatment of P. vivax malaria since it is one of the only drugs
capable of killing hypnozoites and has recently been show to have rapid and potent
gametocytocidal activity in P. falciparum (Ashley, Recht, & White, 2014).
The use of primaquine is problematic however due to concerns of hemolysis developing
in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PD), an X-linked
recessive condition that is characterized by incredibly low levels of the titular enzyme
(Cappellini, 2008). G6PD is involved in the pentose-phosphate pathway an essential process for
RBCs, which serves as a source of reduced glutathione, an incredibly important antioxidant.
Since erythrocytes are the primary oxygen carriers in the body, they are at significant risk of
oxidative damage. Without enough glutathione to offset this damage, the RBC is left weakened
and is usually cleared from circulation by the spleen. This defect confers some protection against
P. falciparum malaria possibly because infected cells are more likely to be cleared in this manner
(Guindo et al., 2007).
Nonetheless, though these drugs may be used to treat malaria and indeed, in combination
some are, they are primarily chemoprophylactics that are given to transiently exposed
individuals. People living in endemic regions are consistently re-infected and giving these drugs
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to them in monotherapy would only encourage the development and rapid spread of resistance.
The WHO recommended first-line of treatment worldwide is artemisinin-combination therapy,
hereafter referred to as ACT.

Artemisinin Combination Therapy
Artemisinin is a sesquiterpene lactone first isolated from Chinese wormwood in the
1960s when it was evident that mosquitoes had developed a resistance to DDT and chloroquine
was beginning to lose its effectiveness in much of the world ("Etymologia: Artemisinin," 2014).
The Chinese government began searching for a new drug by undertaking a systematic inquiry
into various plants used in traditional herbal medicines to find some new antimalarial. The herb
Artemisia annua or qinghao was one of these hundreds of species examined. In the
pharmacopeia consulted, it was listed as being cool in nature, yin, so as to be useful in treating
internal heat, yang. Indeed historical text points to it being implicated in the treatment of an
“intermittent fever illness” in 1596 AD (Cumming, Ploypradith, & Posner, 1996).
Based on the information in these texts, scientists successfully extracted the crystallized
artemisinin compound. Over the next few decades, they demonstrated its potent ability to clear
infection in mice and even in military volunteers (Faurant, 2011). They found no obvious side
effects and that it was much more effective than any other drug at clearing both blood-stage
infection as well as more complicated cases of cerebral malaria. Politics at the time kept this
information from western organization like the WHO until the 1980s, when much progress was
made in a short time.
Its unique structure is the basis of its antimalarial property. The endoperoxide linkage
contained in the 1,2,4-trioxane ring acts as a trigger for artemisinin to release a cascade of
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reactive oxygen radicals in the vicinity of the parasite. Specifically, this process occurs in
response to the plasmodium’s obligatory digestion of hemoglobin and generation of hemozoin.
Hemozoin is formed through biocrystallization of the insoluble iron complex released by
hemoglobin consumption. Often called malaria pigment, the current theory suggests its
interaction with artemisinin to form cytotoxic iron-oxo intermediates as well as electrophilic
alkylating agents that together cause fatal damage to the protozoan (Meshnick, 2002).
Artemisinin combination therapy is presently the most effective treatment option for
uncomplicated P. falciparum malaria. The combination consists of an artemisinin compound
such as artesunate, dihydroartemisinin or artemether being accompanied by an often-slower
acting and different class drug. Currently there are five such combinations recommended by the
WHO: artesunate-mefloquine, artesunate-amodiaquine, dihydroartemisinin-piperaquine,
artemether-lumefantrine and artesunate-mefloquine (WHO, 2014). These drugs are normally
administered as fixed-dose formulations together in one tablet, except for artesunate-mefloquine,
which is given as loose dose i.e. two separate tablets that are packaged together. There are
several advantages to the use of these drugs in this manner, namely their ability to act on all
asexual stages, reducing parasite biomass by approximately 10,000 fold per life cycle rapidly
alleviating symptoms as well as the reduction of gametocyte production and curbing of further
transmission. Additionally, these drugs can affect parasites with multiple drug resistances and
overall have better potency, faster efficacy and delay the development of resistance (WHO,
2014).
In recent years the latter has not proven to be enough. Anywhere from 3% to 50% of
patients fail the treatment and experience parasite recrudescence in monotherapy (Cheng, Kyle,
& Gatton, 2012). Such a wide range of failures correlates with both duration of the treatment,
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with the highest rates corresponding to the shortest treatment times, and size of the parasite
burden. Essentially, individuals with high parasitemia who are not treated for a long enough
period to overcome ART’s short half-life will have parasites survive the drug administration and
persist in their infection (White et al., 2009). Although increasing the duration of treatment
reduces these instances, it does not eliminate them and furthermore isolates of parasites collected
from these patients remain susceptible to the drug in vitro (Teuscher et al., 2010) indicating that
the cause of these outcomes is not outright resistance. Although combination therapy seems to be
assuaging these events, reports of decreased sensitivity has had many fearing recrudescence as a
mechanism toward the establishment of resistance.
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BACKGROUND
Recrudescence & Dormancy
Recrudescence is a phenomenon common to Plasmodium parasites and is often
considered a sign of treatment failure although that many other factors can also contribute
including improper dosing, poor compliance among patients, and poor quality of drugs
administered (Cheng et al., 2012). The term itself is defined as a situation in which a patient’s
parasitemia drops below detectable levels before increasing at a later time. This phenomenon
differs from relapse, which specifically refers to the re-activation of the dormant hypnozoites in
the liver of individuals infected with P. vivax or P. ovale (Hulden & Hulden, 2011). However
there is evidence indicating that a similar quiescent stage is the causal mechanism behind what is
hypothesized to be an adaptive stress response (Cheng et al., 2012).
Such a failure of treatment and subsequent recrudescence is required in nearly all cases of
newly developed drug resistance. In simplest ecological terms, administration of antimalarials
bottlenecks the parasite population toward the least susceptible subjects, which go on to produce
gametocytes that may possess some adaptation against the drug of choice. The risk is
exacerbated in individuals with high parasite burdens. It is logical to assume that more severely
ill patients will have a higher chance of being treated and thereby a higher chance of their
treatment failing. By extension, treatment failure often entails further treatment and thus a
second opportunity to bottleneck the parasite population and once again, select for the least
susceptible protozoa. In fact, observations of resistance development have been consistently
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preceded by recrudescence events. A pilot study performed in Ghana in 1962 first noted this
association where an abundance of treatment failures eventually led to pyrimethamine resistance
resulting from improper self-medication (Charles, 1962). The patients who experienced
recrudescence had parasites that remained less susceptible to pyrimethamine over the
observation period.
To determine whether dormancy could be a plausible explanation for some failures of
ART treatment, Codd et al created an infection model to simulate P. falciparum interaction with
host immune response incorporating both antigenic variation of the parasite and the parameter of
dormancy induction (Codd et al., 2011). The latter was expressed via a daily dose of artemisinin
(ART) for 1, 3 or 7 days, which killed all but a small percentage of parasites. These parasites
would later re-emerge at the same stage that they went dormant, expressing the same surface
receptors under the assumption that ART targets immature stages more readily.
All simulated infections had some level of recrudescence due to the presence of dormant
stages, however just a small proportion of these could be measured clinically due to the
intervention of the immune system. This observation makes sense as it has been demonstrated in
numerous studies that natural immunity often develops following repeat exposures. Furthermore
their simulated failure rates were comparable to that observed in clinical field trials thus
providing legitimacy to the hypothesis that dormancy and treatment failure are linked (2011).

Drug-Induced Dormancy
Previously published in vitro data have demonstrated that the short half-life of
artemisinin drugs results in a plasma concentration of the drug above the minimum inhibitory
concentration (MIC) (Teuscher et al., 2010). This period allows some parasites to escape
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exposure and thereby maintain a minute yet significant population for the infection to persist.
These explanations do not hold up to scrutiny, however, in cases where the treatment length is
increased and recrudescence still occurs.
The alternative supposition holds that surviving parasites enter a quiescent stage of little
to no growth similar to that occurring in P. vivax hypnozoites. These so-called dormants endure
the drug treatment and recover once it is discontinued. Laboratory studies demonstrate that
parasites at the ring stage when exposed to an artemisinin derivative such as artesunate or as is
used in this thesis dihydroartemisinin (DHA) will tolerate said treatment by rapidly arresting
their growth in a dose-dependent manner.
These drug-induced dormant parasites are morphologically distinct from their ring-stage
asexual counterparts with a condensed cytoplasm and an overall much smaller size. In this stage,
the parasites exhibit a reduced metabolism, which may be measured through the stage-specific
expression of luciferase-transfected parasites. Bioluminescence reporters are common tools in
ascertaining various biological functions in a quantitative manner (Khan et al., 2012). It is an
enzyme-catalyzed process where photon emission is derived through the completion of an
exothermic reaction namely between the luciferase enzyme and its substrate, D-luciferin. Firefly
luciferase from Photinus pyralis is an enzyme requiring no post-translational modification
meaning it can be successfully transfected into malaria parasites and has, by members of the
Kyle lab with the laboratory strain 3D7 and patient isolate 4G.
Luciferase acts by first combining its substrate with ATP to form the intermediate
luciferyl-AMP which promptly reacts with oxygen to create another, oxyluciferin. The latter
being in a high-energy state allows its transition back to ground to yield a yellow-green light,
which can be detected by a luminometer. As ATP content is an indicator of metabolic status, it
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can conceivably be used to detect abnormal metabolic activity imposed by drug action (Azevedo
et al., 2014). Transfected parasites produce the luciferase enzyme and produce more of it
depending on the stage that they are in. In this way, higher relative light units (RLUs) are
indicative of the presence of more mature stages and signs of their growth and recovery.
Dormant parasites do not exhibit high levels of ATP by the very nature of their quiet state; they
are not proliferating.

Dormancy in Exoerythrocytic Stages
Dormancy is not a new concept. As was mentioned in brief, there exists a point in the life
cycle of P. vivax and P. ovale where quiescence occurs (Mueller, Zimmerman, & Reeder, 2007).
During the liver stage while the majority of infective sporozoites are developing into schizonts
and bursting from their host hepatocytes to release merozoites into the bloodstream, a small
population remains. The precise mechanism behind dormancy induction and reactivation is
unknown, although there has been informed speculation regarding why P. vivax parasites
hibernate in this manner.
The length of dormancy seems to vary across strains with the longest being seen in places
like Finland and northern Moscow where relapse can last 9 years and the shortest in New
Guinea, only 17 days (Hulden & Hulden, 2011). While the differences in dormancy of
hypnozoites may be explained by polymorphic differences among P. vivax strains, variation
among relapse times seems to directly correlate with the seasonal variation of the mosquito. An
unpredictable vector population appears to be a key ingredient for a long dormancy period and
furthermore, relapse may be triggered by the bites of new vectors. A study in the UK
demonstrated that onset of vivax malaria was restricted to the summer months regardless of
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when the infection was contracted, and despite the vast dissimilarity in patient incubation periods
(Venkatesan et al., 2003)
Several advantages exist for hypnozoite development with the foremost being the
amplification of the likelihood of a parasite reaching its vector, as the host may be infective on
multiple occasions. This advantage is maximized if the awakening of hypnozoites is not random
but in response to some trigger by the mosquito vector. Since sporozoites only infect the salivary
gland, it may be supposed that the hypnozoites hiding in their hepatocyte hosts may be able to
recognize something within the mosquito saliva (Hulden & Hulden, 2011). More research is
required to determine if such a compound exists but exploiting it could potentially induce a
relapse and allow parasites to be targeted by other medications.
Both of these stages represent an arrested developmental state with the key difference
being causality – one is induced by drug stress in the blood while the other by the parasite’s
metabolism as it waits to be transmitted. On a related note, although not referred to as dormant,
stage IV and V gametocytes also appear to have a quiescent component to their developmental
track. While most drugs targeting the blood stages also affect young gametocytes (stages I – III),
the mature stage V is not sensitive to their effect (Miguel-Blanco et al., 2015). It is believed that
they instead remain in a state of relative inactivity for up to 22 days in the peripheral
bloodstream until either being picked up by a feeding mosquito or dying. Since the mechanism
of dormancy induction is not yet understood, there exists the possibility that the contributory
method is similar among P. vivax hypnozoites and P. falciparum quiescent stages. Thus testing
of compounds against the induced-dormant phenotype could be informative for more than one
circumstance and encourage further study.
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Dormancy in Other Organisms
A common feature to many microorganisms, dormancy is a trait that allows a species to
respond to the temporal irregularity of its environment. It is thought to be important in natural
systems, some 20 – 80% of microbial samples appear metabolically inactive and many can be
resuscitated with supplements of required resources (Jones & Lennon, 2010). It is regulated by a
multitude of environmental cues and many microorganisms that resist temperature changes,
desiccation, and antibiotics do so by entering a non-proliferating dormant stage. The ubiquity of
this characteristic behavior comes as no surprise, mathematical models have demonstrated that it
influences species richness and microbial diversity by ensuring survivability during times that
would be inhospitable otherwise (Jones & Lennon, 2010).
In baker’s yeast, Saccharomyces cerevisiae, quiescence is often styled as a “Sleeping
Beauty” state (Gray et al., 2004) and can be induced by a limitation of nutrients. In this way,
dormancy induction can be described as a survival mechanism (Markus, 2012). In humans, tissue
homeostasis and post-injury regenerations are facilitated by adult, sometimes tissue-specific,
stem cells (ASCs) (Rumman, Dhawan, & Kassem, 2015). These cells are sustained inside normal
tissues in an undifferentiated and dormant state. They are activated following the advent of an
injury through the production of mechanical signals at the site of injury. These signals lead to an
amplification of the ASCs, which eventually differentiate into the appropriate cell types.
Cellular quiescence in this sense is a transient stage wherein the cells have exited the cell
cycle. Commonly called G0, the cells contain an unreplicated genome, altered and slowed
metabolism, an increase in autophagocytosis and a markedly distinct morphology – one that has
already been described among P. falciparum dormants. Cell cycle arrest is reversible however,
making it different from that seen in terminally differentiated, dying cells (Rumman et al., 2015).

15

Tuberculosis
Recurrence in tuberculosis infections has been a distinguishing feature for years, slightly
less so in modernity, which saw the advent of combination therapy in the usage of isoniazid
(INH), rifampin (RIF), and pyrazinamide (PZA). Statistically, reactivation risk was reduced from
20% in the 1960s to today’s rates of 1 – 2% (Gomez & McKinney, 2004). These numbers may
not be wholly representative as historically no note was made concerning reactivation versus
secondary infection. On a global scale, this continues to be the case and geographical constraints
are used to provide some distinction. Areas of high transmission are typically considered to have
more re-infections while the opposite is true of areas of low transmission, where more
recurrences are to be expected.
When it comes to the disease itself, it is important to define the key terms utilized in
describing pathogenesis (Gomez & McKinney, 2004). Latency is the presence of a TB lesion that
does not produce any discernable symptoms. An individual may be in a latent infection prior to
the onset of overt disease or after a spontaneous resolution. Without treatment, chronic latency is
considered the typical TB outcome and the infection may reoccur even after years of no clinical
signs. Latent infections are also transmissible. Persistence specifically refers to continuous
infection in times of adversity such as under drug pressure. The mycobacterium can be
incredibly resilient, the mere fact that it uses macrophages as its cellular host is a demonstration
of its ability to persist despite its environment. Another example is the incredibly difficult and
the slow rate at which anti-TB drugs clear the bacteria. This feature has made its treatment a
challenging one especially in the developing world.
Lastly, dormancy in TB may describe the nature of the disease in addition to the
metabolic conditions inside the characteristics tubercle. It was first used to explain the state of
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bacilli that survive in closed and necrotic lesions during clinical latency. Though this model was
quite speculative, it brought the idea of dormancy to the forefront. In the 1940s surgical removal
of lesions was common and allowed scientists to study the bacteria therein. By the 1950s, there
were several reports showing the presence of acid-fast bacilli within lesions removed from
patients that have been undergoing treatment and testing sputum-negative. Some of these bacilli
were culturable but those taken from closed lesions were not. The debate began regarding
whether unculturable bacteria were truly dead or dormant. Through the work of several teams of
scientists and over the past two decades, it was postulated that the aforementioned conditions
within these particular lesions contributed to their dormant response. Specifically lowered
oxygen stress, as well as the presence of substances such as long-chain fatty acids, lactic acids
and others with bacteriostatic properties (Gomez & McKinney, 2004). Together they reduce
bacterial metabolism and render the tubercle bacilli defiant to drug pressure. Since all present
medicines are aimed at targeting cell division and growth, it makes sense why they exhibit such
poor activity against these lesions.

Cancer Cells
Dormancy among tumor cells is an occurrence that has been known to clinicians for
many years. It was first identified in the 1940s and redefined in the 1950s as a temporary mitotic
growth arrest. Arresting of growth occurs naturally due to cell aging or senescence; it is
triggered by numerous signals like oncogene-induced stress (Sosa, Bragado, & Aguirre-Ghiso,
2014). Unfortunately, as was already mentioned this is an irreversible process and could not be
the mechanism behind dormancy. However, since the cells are no longer proliferating, it stands
to reason that they are in a G0/G1 arrest.
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It is just as poorly understood as that which occurs in microorganisms though somewhat
more complicated. The term has been used loosely to refer to cells “lying in wait” but abundant
evidence exists to point to its involvement in numerous malignancies specifically in the
phenomenon of metastasis. Metastasis is a rather inefficient process. Although metastases may
form from just a subset of cells, the cancerous progeny that develop exist in three distinct states,
only one of which is clinically detectable (Goss & Chambers, 2010). The other two,
micrometastates, somewhat dormant cells whose growth is balanced through apoptosis, and
solitary, true dormant cells may only be detected through histology. In other words, the actual
extent of dormancy in affected cells is not well understood.
Persisting in a quiescent state may allow the disseminated tumor cells (DTCs) to avoid
treatment in a number of ways, the most obvious being their dormant nature but also the fact that
the cells disseminate at early enough stages to allow themselves to diverge genetically from the
primary tumor (Sosa et al., 2014). The crux of the issue is then targeting as the therapies devised
according to the characteristics of the primary tumor no longer apply. There is also some
evidence of the existence of pre-metastatic niches or areas that contain different host cell types
capable of “cross-talking” with the DTCs. These niches thenceforth support the dormants as well
as their growth and evolution.
Whereas with dormant malarial infections, there could be some advantage to finding a
compound to wake the parasites in combination with drugs like DHA and piperaquine to ensure
as high a clearance as possible. In the case of tumor cells, this is not recommended due to the
lack of available effective and specific cytotoxic treatments (Sosa et al., 2014). Additionally
because DTCs are genetically heterogeneous, awakening dormant ones would only expand the
genetic and possibly epigenetic diversity therein, potentially spreading mechanisms of resistance.
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Instead present research is concentrated in either keeping DTCs dormant or determining a
method for eradicating them despite their dormancy.

Dormancy in Plants
Unlike most other organisms, plants are bound to their locations and truly at the whims of
their environments. It is for this reason that they have established a cyclic pattern of
developmental states, alternating between growth and non-growth. Transitions between these
phases are tightly regulated to ensure that the most vulnerable stages occur during the most
favorable of times. These two stages are bud dormancy and seed dormancy (Graeber et al.,
2012). A decent example of the former would be prevention of bud growth in perennial plants
during winter months (Rohde & Bhalerao, 2007). Both intervals are depicted as being times of
very low metabolic activity and insensitivity, albeit temporary, to signals promoting growth.
An innate property, seed dormancy is a key determining factor in germination times. It is
essentially a plant’s adaption to the diversity of its habitat, with a genetic basis and heavy
environmental influence. As a quantitative trait, its intensity can vary over time. In fact, seeds
typically experience a primary and a secondary dormant state (Graeber et al., 2012). Primary
dormancy occurs immediately following maturation of seeds and grows more pronounced during
drying and storage. It can however wane depending on the conditions for germination being met.
Conversely, secondary dormancy occurs when seeds on the cusp of activation are re-induced
typically in stints of high or low temperature. In this way, plants and their cultivators can control
both when germination occurs and how many seeds sprout.
Dormancy induction is coordinated by a diverse group of regulators at different times
with different levels of specificity. The two main and antagonistic hormones are abscisic acid
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(ABA) and the gibberellin group of hormones, of which gibberellic acid (GA) is the most wellknown (Graeber et al., 2012). Their balance within a plant is vital for controlling both induction
and maintenance of dormancy. As will be elaborated in subsequent sections, they also appear to
have an effect on the drug-induced dormant state of P. falciparum, indicating that the latter must
possess similar pathways and possibly a similar mechanism for its own quiescent response.

Plasmodium Plant Origins
The Plasmodium genus, consisting of some 200 species of parasitic protozoa, is a
member of the Apicomplexa phylum, so named for its unique possession of an apical complex –
a collection of anterior structures that play a key role in cell invasion and the establishment of
infection. This apicoplast is actually a relict plastid whose origin and function have been
extensively studied since its discovery in the 1990s (Lim & McFadden, 2010).
All plastids, from chloroplasts to leucoplasts, are the results of an endosymbiotic
relationship between an ancestral prokaryote and its eukaryotic host. Evidence exists to support
the notion that all plastids are resultant from a single such event with a cyanobacterial organism.
The apicoplast falls within this group of exogenous organelles and is distinguished as a
secondary plastid being the product of one eukaryote engulfing another, this other containing a
primary plastid of the aforementioned cyanobacterial variety (Waller, 2004). Over time the latter
eukaryote was stripped of its superfluous features and most of its genes assimilated with those of
the host. The only remaining evidence of its previous existence is the continued presence of three
or four membranes. This is in contrast to a primary plastid, which would only have two; these
being homologous to the membranes of the Gram-negative bacterium from which they were
derived.
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As far as P. falciparum is concerned, each parasite contains just one apicoplast, which is
intimately linked to the mitochondrion throughout the asexual stage of its life cycle. The exact
reason for this association is presently unknown. Although, a recent study by Kobayashi et al
found the first experimental evidence that there exists an actual physical bond between the two
organelles. Their hypothesis as to why this association occurs involves heme biosynthesis in
which both the mitochondrion and the apicoplast are known to be involved. The production of
one component (5-aminolevulinic acid) seems to begin in the former and continue in the latter.
Their proximity may be a requirement for successful transportation across the multitude of
membranes (Kobayashi et al., 2007).
Despite lacking the photosynthetic capabilities that better-known plastids are
characterized by, the apicoplast has proven itself to be essential to the malaria parasite and
indeed to most Apicomplexans. Drugs that target its transcription ultimately lead to the death of
the protozoan. Parasites engineered to lack the organelle are able to invade tissues and multiply a
few times but eventually decline and die implying its importance in maintaining metabolism
(Lim & McFadden, 2010). Furthermore, proteome analysis has shown apicoplast involvement in
the biosynthesis of fatty acids, heme, and isoprenoids. These functions are analogous to those
occurring in plant plastids.
Isoprenoids, also sometimes called terpenoids, are a vastly diverse group of natural
products that are found in all organisms and have important functions therein. They are made up
of repeated units of isopentenyl pyrophosphate (IPP) or its isomer, dimethylallyl diphosphate
(DMAPP) (Jordão, Kimura, & Katzin, 2011). The former is synthesized by one of two pathways
distinguished by the presence or absence of mevalonate. The classic pathway supplies IPP to
most if not all eukaryotic animals including all mammals, some bacteria, algae, and higher plants
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as well as the Trypanosomes, namely Trypanosoma and Leishmania parasites. In humans IPP is
required to initiate the biosynthesis of cholesterol and indeed, statins target HMG-CoA
reductase, a key enzyme at the start of this pathway. Alternatively, the mevalonate-independent
pathway also called the methylerythritol phosphate (MEP) pathway is specific to photosynthetic
organisms like cyanobacteria, algae, plants, and most fittingly, apicomplexan parasites and M.
tuberculosis (Jordão et al., 2011).
In Plasmodium, isoprenoids serve as precursors to compounds involved in electron
transport and glycoprotein formation and also act as prosthetic groups on various enzymes
(Waller, 2004). The apicoplast synthesizes these compounds via the MEP pathway and is the
only site to do so. This fact has opened new avenues of research since several enzymes from this
pathway are wholly absent in humans and could serve as excellent targets for drug development.

Phytohormones and Dormancy
As was stated in a preceding section, plants utilize two distinct hormones for regulation
of growth. These work antagonistically in intricately linked pathways to both induce and release
a seed from dormancy. ABA, a carotenoid catabolite, produced during later stages of maturation
and whose levels appear to correlate with day-length, inhibits division, and lowers overall
metabolism (Zheng et al., 2015). The specific mechanism for ABA’s influence is beyond the
scope of this thesis but it requires mentioning that its presence appears to directly influence
dormancy induction. In light of the function of the apicoplast and the synthesis of IPP, a
precursor for carotenoid biosynthesis among many other processes, the Kyle lab is currently
researching ABA’s role in drug-induced dormancy. Having detected its presence in the
erythrocytic stage and further quantified its levels in response to carotenoid inhibitors and
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apicoplast-targeting substances alike, the present hypothesis poses that ABA may act a stress
sensor in P. falciparum, regulating the dormant response (Duvalsaint, unpublished data).
Conversely gibberellic acid controls growth in opposition to ABA by stimulating mitotic
division and increasing the germination of seeds (Toyama et al., 2012). It too may have an effect
on the aforementioned induced-dormant state and warrants investigating, as it is possible and
even, probable that it may behave similarly. Along the same line of thinking the herbicide
fluridone (FLD) specifically works by inhibiting phytoene desaturase, an enzyme involved in
carotenoid synthesis (Tonhosolo et al., 2009). Preliminary data has demonstrated that in vitro
dormants when exposed to FLD experience a growth delay, effectively keeping the parasites in
their quiescent state longer.

MMV Malaria Box
Medicines for Malaria Venture (MMV) is non-profit organization established in
Switzerland in 1999 who’s mission is to reduce the burden of malaria by discovering, developing
and facilitating new and affordable antimalarial drugs (Ridley, 1999). As a part of this
facilitation, they provide the appropriately named Malaria Box to researchers in malaria and
other neglected disease fields. The box contains 400 diverse compounds generated from 20,000
hits, which were gathered in an extensive screening campaign of almost 6 million compounds
from the libraries of St. Jude’s Children’s Research Hospital, Novartis, and GlaxoSmithKline
(Spangenberg et al., 2013). Originally screened for efficacy against asexual blood stages of P.
falciparum, it was also tested for cytotoxicity and all compounds included are those with 10-fold
less potency against human cell line than the P. falciparum target. To date, these boxes have
been dispatched to 27 countries and tested against a wide variety of targets including malaria but
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also other neglected disease such as trypanosomiasis, leishmaniasis, schistosomiasis, TB, and
Naegleria fowleri.
The 400 compounds are provided as five 96-well plates of 10 mM stock solutions in
100% DMSO (Lucantoni et al., 2013). Plates are divided by drug- and probe-like characteristics
by which the compounds are grouped with the first plate consisting of the 80 most active of both
categories and the other four comprising two plates of drug-like and probe-like, respectively.
Prior to this distinction, compounds were chosen to achieve maximum diversity and crossreferenced with commercial availability. Half of the selected 400 were qualified as drug-like for
being rule of 5 compliant (Spangenberg et al., 2013).
Prior to Chris Lipinski establishing the now widely used rule of thumb for determining
the physiochemical features of a potential drug, many clinical candidates would fail
development. The rule covers the ADME criteria regarding the outlook of a pharmacological
compound within an organism. Specifically absorption, distribution, metabolism and excretion
are purportedly managed by certain molecular properties the rule encompasses. The rule thusly
states that an orally active compound must have a molecular weight below 500 D, a partition
coefficient log P no greater than 5, no more than 5 hydrogen bond donors and no more than 5
hydrogen bond acceptors (Lipinski, 2004). Meeting these guidelines does not guarantee that a
compound will be effective, it simply uses information from previously identified drug-like
compounds to determine the probability that a compound of interest will not encounter any
issues in its oral activity. The REOS (Rapid Elimination of Swill) and PAINS (Pan Assay
Interference Compounds) filters further analyzed MMV drugs that did not meet one of these
criteria and following this second review; the second category of probe-like was established
(Spangenberg et al., 2013).
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AIMS & OBJECTIVES

The first objective of this investigation was to confirm the effect of gibberellic acid and
fluridone on drug-induced dormant P. falciparum and to optimize such an assay for screening.
Secondly with the prior two compounds as comparative controls, the goal of the initial MMV
screen was to find those compounds, if any, that behave similarly and are able to either wake a
DHA-induced dormant as GA or conversely, to induce the parasite to remain dormant beyond
the typical recovery period as FLD.
The third objective was to screen P. falciparum in absence of DHA exposure and
determine whether any MMV Malaria Box inhibitors triggered a dormant phenotype response.
The hypothesis being that a response to stress in the parasite is to become dormant, it stands to
reason that drugs other than artemisinin and its derivatives are capable of inducing its initiation.
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METHODS
Plasmodium falciparum Culturing
Plasmodium falciparum parasites were routinely maintained with 10% complete media
(CM) and O+ blood. Specifically 3D7 a chloroquine-sensitive laboratory strain and 4G, a
patient-isolate clone, both having been previously successfully transfected with the luciferase
reporter. Slides were taken daily and media changed on alternating days. If parasitemia was
determined to be greater than 3%, cultures were split down and red blood cells (RBCs) were
supplanted. On days that an assay was to be performed, cultures were synchronized at the ring
stage with 5% D-sorbitol. Samples were frozen when parasitemia was high for maintenance of
stock and thawed when needed for experimentation.

Freezing and Thawing Protocols
Cultures at high percent parasitemia with a predominance of rings were centrifuged at
9,660 xg for 5 minutes at 4o C. The resultant supernatant was then removed with a 5 ¾”
unplugged Pasteur pipette attached to the intake line of a standard laboratory vacuum. The
volume of the packet cells was then estimated, dubbed V1 and glycerolyte was added drop-wise
at 0.33x of this volume. Obtained from Baxter Blood Products, glycerolyte solution consists of
57% glycerol buffered with sodium lactate, and potassium chloride filtered through a sterile 0.22
µ vacuum filter before use.
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The new volume of packed cells and glycerolyte, V2, was allowed to stand at room
temperature for 5 minutes before more glycerolyte was added at 1.33x of this new volume.
Samples were finally divided into aliquots of 400 µl into sterile cryotubes labeled with the name
of the clone, its present parasitemia and the date of its freezing. Tubes were then placed and
stored in a – 80o freezer.
Thawing samples involved essentially reversing the above steps. Cryotubes were
immediately placed in a 37o water bath for 1 – 2 minutes and then transferred into a 50 mL
sterile centrifuge tube; this volume was dubbed V1. 12% NaCl was then added drop-wise at 0.1x
volume of V1 while the tube was swirled. After allowing the new volume, V2, to stand for 5
minutes 1.6% NaCl was added at 10x said volume. The tube was then centrifuged at 9,660 xg for
5 minutes. The supernatant was removed, 0.9% NaCl was added and also removed in the same
manner. The resultant pellet was then re-suspended in 15% CM and washed, spun and resuspended again with 150 µl of fresh red blood cells in a sterile, vented culturing flask which in
turn was placed in a mixed gassed incubator for 24 hours.

Plasma, Media and Blood Preparation
Plasma was obtained from Interstate Blood Bank and promptly heated in a water bath for
60 minutes at 60o then refrigerated at – 4o for 15 to 20 minutes before being sterilely transferred
to 500 mL conical centrifuge bottles, which were thereafter centrifuged at 842 xg for 15 minutes
at 4o C. Care was taken to avoid the lipid/protein layer that precipitated out when pooling plasma
pots before aliquoting into 15 mL centrifuge tubes which were frozen and stored at – 80o.
Blood, a crucial ingredient for culturing and experimenting with P. falciparum, was
processed on a weekly basis when received, likewise from Interstate Blood Bank. Bags were
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thoroughly sterilized before being aliquoted into 50 mL centrifuge tubes in a suspension of
RPMI 1640, HEPES and sodium bicarbonate then spun at max speed in four successive
increments of 15, 5, 5 and 15 minutes. After each spin, the supernatant and buffy coat were
removed until eventually the final pellet was matched with an equal volume of this washing
media for a working suspension of 50% hematocrit. RBCs were stored at – 4o for approximately
one week at a time.
The CM that has already been mentioned in previous paragraphs is similar to the blood
wash media in that it consists primarily of RPMI 1640. When HEPES and sodium bicarbonate
are also added, the media simulates the environment found in human blood via a bicarbonate
buffer system. For the purposes of routine culturing 100 mL of CM was made with 10% plasma
consisting of 86.8 g RPMI, 3.2 g NaHCO3 and 10 mL pre-warmed plasma. Phenol red is a pH
indicator that was included with the standard culturing media but left out during assays primarily
because the luminescence signal proved stronger without its presence.

Slide Preparation
Slides were taken daily to determine parasitemia and gain a snapshot look into the
parasite culture’s health. Spent media was aspirated and the flask set on its end so as to allow
cells to settle. A sample of 2 µl was removed using a 10 µL pipette. One drop was placed on the
front of the clean glass slide, this being the thick smear, while the remainder of the aliquot was
dispensed towards the middle, the thin smear. Using another clean slide this second droplet was
spread along the surface smoothly and the whole slide was allowed to dry before being fixed
with methanol and stained with 20% Giemsa for 15 minutes, after which it was promptly rinsed
with cold water and allowed to air dry.
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Parasitemia counts were obtained by examining prepared slides under 100x magnification
with immersion oil. Areas of 100 – 200 red blood cells were identified and quantified as fields of
which 5 total were used to form an average percentage. If parasitemia was greater than 3% the
culture was “split” meaning a sample of the infected red blood cells was transferred to a new
culture flask with an appropriate amount of fresh blood and fresh media according to the simple
calculation: C1V1 = C2V2 with the new concentration corresponding to a lower, desired
parasitemia.

Dormancy Induction
Slides were taken as described in the previous section and if found to be predominantly
ring stages, the culture was transferred with a 10 or 25 mL pipette from its flask to a 50 mL
centrifuge tube, then spun for 5 minutes at 9,660 xg. The supernatant was removed via aspiration
and replaced with pre-warmed 5% D-sorbitol. The tube was then placed on a shaker for ten
minutes and centrifuged again at the same settings. The supernatant was removed and the culture
was washed 3 times with RPMI 1640 without phenol red, the final washing step included the
addition of an appropriate amount, typically 10 or 20 mL of CM, also without phenol red. The
new culture was left to stand at room temperature for ten minutes and a second slide was taken to
determine new parasitemia.
Volume varied depending on the requirements of the particular assay being performed
but DHA’s concentration was kept constant at 700 nM. After adding the latter to the culture
flask, it was allowed to incubate for 6 hours with DMSO-exposed infected RBCs and unexposed
RBCs as positive and negative controls, respectively. Following this period, each culture was
transferred from its flask to a 15 mL tube and centrifuged for 5 minutes at 9,660 xg. The
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supernatant was removed and fresh RPMI 1640 was used to wash out the drugs three times with
repeated spins and subsequent removal. A multichannel pipette was then used to plate and set up
the particular assay being performed while 2 µl of DHA-exposed, DMSO-exposed and
unexposed RBC’s were removed for preparing slides to confirm dormancy induction.

Drug Assays
The ring stages of P. falciparum were exposed to DHA as described above in order to
induce dormancy and use the recovery period as the screening period for potential inhibitors. The
P. falciparum strains utilized were stably transfected with luciferase enzyme meaning that each
assay used bioluminescence measured in RLUs as basis for measuring activity.

Optimization
The goal of optimization was to determine which percent parasitemia was most effective
for observing recovery and to determine whether the positive and negative controls were
appropriate comparative measures of activity. Parasitemia and predominating life stage was
determined via microscopy after which the culture was synchronized with 10 mL of 5% Dsorbitol for ten minutes, washed 3 times with RPMI 1640 and new parasitemia counts were
made. Based on this information, three centrifuge tubes were used to make 4 mL aliquots each at
2% hematocrit with 0.5%, 1.0% and 2.0% parasitemia as the main testing variable, in a separate
tube a 2% hematocrit suspension of red blood cells was made at 1 mL. Using a 5 mL pipette
these cultures were transferred to a 6-well plate with the top row containing 2 mL of each
parasitemia and 16 µl of DHA whereas the bottom row, the control, contained 1 mL of each
parasitemia and 8 µl of DMSO, a separate plate contained the RBC suspension.
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All were incubated for 6 hours to induce dormancy, transferred to falcon tubes and
washed 3 times with RPMI 1640. A multichannel pipette was used to transfer cultures to a 96well plate and 10 µl of D-luciferin was added to each well. Luciferin stock consists of 30 mg/mL
of D-luciferin in 1 mL of PBS at pH of 6.1 – 6.5, this is then diluted 1:20 prior to use or 300 µl
of stock in 5.7 mL CM. Plates were sealed and read by a TopCount Luminometer at the 0 hour
and 6 hour time points then each subsequent day at the original incubation time until recovery of
dormancy could be definitely observed.

Dormancy Recovery Test
To determine the typical period of recovery, dormancy was induced as previously
described and a 12-well plate was set up with 1 mL of parasite suspension per well as well as 8
µl of DMSO in the first row and 8 µl of DHA in the second, the third was left empty. Half the
tested culture was kept at 1% parasitemia and 2% hematocrit while the other half at 2%
parasitemia and 4% hematocrit. 90 µl were transferred daily to a column of a 96-well plate
complete with 10 µl of D-luciferin. Additionally 2 µl were taken for slide preparation and the
cultures were fed every two days to maintain both volume and concentration being tested.
This recovery test was performed for 3D7 and 4G with recovery being monitored by both
luminescence values and by the microscopic detection of phenotypic changes. Feeding
calculations hinged on the assumption that 180 µl of culture was removed every two days and
that the numbers of infected cells could be quantified based on the percent hematocrit used.
Media was thus replaced according to this estimated displacement.
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Dormancy Recovery Assay with GA/FLD
In order to determine what qualifies as a hit when screening further inhibitors, it was
necessary to test and quantify active compounds for such comparison. Gibberellic acid has a
molecular weight of 346.37 g/mol and accordingly 3.46 mg was dissolved in 1 mL of a solution
consisting of 30% H2O and 70% ethanol, this made a stock concentration of 10 mM. This was
further diluted to two concentrations 10 µM and 100 µM of which 10 µl was used in the assay for
final concentrations of 1 µM and 10 µM, respectively.
Fluridone has a molecular weight of 329.32 g/mol and likewise dissolving 3.29 mg in 1
mL DMSO made a stock solution of 10 mM. These were further diluted to 500 µM and 100 µM.
As 10 µl was the volume used in the assay final concentrations were thusly 50 µM and 10 µM,
respectively. Mother plates were made containing 600 µl of each of both drugs at both
concentrations with CM for control.
Following dormancy induction as previously described, 80 µl of 3D7 parasite was
transferred to a 96-well plate with 10 µl of both drug and D-luciferin. Readings were taken at 0
hour and 6 hour time points and then each subsequent day at time of first incubation. On day 2,
the plates were sealed, their lids secured with paraffin and spun at 2,000 rpm for 2 minutes.
Using a multichannel pipette, 80 µl was removed being careful as to not disturb the pellet, 80 µl
of RPMI was added and plates were sealed and spun again after which another 80 µl of this
resultant waste was removed. This was repeated a third time after which the plate had CM only
added to the first four rows and CM with drug as per the mother plate, added to the second four
rows. In this manner, the recovery could be monitored with parasites that were exposed to drug
for 48 hours and parasites being continually exposed.
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MMV Box Screening
As there were 5 plates to process, each with 80 drug or probe-like compounds to screen,
culture was brought to a high parasitemia at 4% hematocrit with estimated need of at least 800 µl
of infected RBCs. Parasitemia was assessed, sorbitol-synchronized and dormancy induced as
previously described. The MMV original plates were diluted from 0.1 mM in 100% DMSO
down to 1 µM in 1% DMSO. Both mother and daughter plates were made with the Biomek robot
and in addition to the drugs to be screened, controls of 1 µM and 10 µM Gibberellic acid, 10 µM
and 50 µM Fluridone, 80 µl of uninfected and untreated RBCs, 80 µl DMSO-treated iRBCs and
80 µl DHA-treated iRBCs.
80 µl of parasite was added to each well containing the MMV compounds with 10 µl of
D-luciferin as well. Plates were read at the 0 and 6-hour time points then incubated at 37o and
read each day at the time of original set-up. Following 48 hours after initial exposure, plates were
spun and washed three times with RPMI 1640 after which CM was replaced and plates reincubated and continued to be monitored daily for RLU values indicative of recovery.
This experiment ultimately yielded very few hit compounds so that the experiment was
repeated at 2 µM concentration, 2% DMSO. The controls were adjusted to the latter parameter
and likewise plates were monitored until recovery was evidenced in the luciferase readings.

Dormancy Induction Screen
To determine if any of the MMV compounds are capable of inducing a dormant
response, the plates were processed in the manner described above at 2 µM and 3D7 alone was
added. Controls remained the same. The plates were incubated at 37o C for 48 hours, after which

33

they were washed 3x with RPMI and from each well a slide was made. These slides were then
analyzed for activity and categorized as being “hits” if any dormant parasites were present.

Confirmation Assay
The 32 compounds that qualified as hits in the aforementioned screen were extracted
from the mother plate, diluted to 2 µM once again and added to a 24-well plate containing 500 µl
of 3D7 at 2% parasitemia, 4% hematocrit. Plates were allowed to incubate at 37o for 48 hours
just as in the previous experiment; upon which they were washed 3x with RPMI and media was
replaced. A 90 µl sample was taken at this time for luciferase readings and slides were made
daily. At the first sign of recovery, the plates were placed at a tilt, the cells allowed time to settle
and the media promptly aspirated and replenished to maintain the 4% hematocrit. Culture and
slides were maintained until either recovery or lysis was observed first. The figure below
demonstrates the morphology present at the start of the experiment i.e. predominately ring stages
at a relatively high parasitemia of 10%, for comparison see Table 2 of the dormant phenotype.

Figure 1. Morphology of 3D7 Plasmodium falciparum prior to DHA-exposure
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RESULTS

Dormancy Induction & Recovery
First it was important to determine at what parasitemia to perform further assays. The
surface area of a 96-well plate is less than half a milliliter and can consequently become
overwhelmed if parasitemia and/or hematocrit become too high. Tightly synchronized 3D7
parasites were used for each experiment, typically at a 10% or higher parasitemia of exclusively
rings. Following exposure to 700 nM DHA for 6 hours, parasites were transferred to a 96-well
plate and monitored until recovery.
The optimization assay depicted in Figure 1 illustrates the rapid drop-off of activity that
occurs within the first few hours, and continues until the 3rd day where a slight increase was
measured via the luciferase reporter. The parasites seem to recover around the 5th day of
incubation, and would have continued to grow had the experiment not been stopped on day 8.
Background levels, corresponding to that of the negative control uninfected RBCs, were low
never much higher than 50 RLU. The parasitemia with the peak rate of recovery was 2% and this
is the one chosen for the remainder of assays attempted.
Figure 2 illustrates the second objective of optimization that is ensuring that the controls
used are appropriate for observing normal growth and activity with relative luciferase units
(RLUs). The growth curve of DMSO demonstrates the stage-specific expression the transfected
enzyme is known by. Khan et al validated this association by culturing parasites at the
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trophozoite stage, measuring their ATP values narrowly and accompanying this data with
hematocytometer counts of parasitemia every two hours during a 10-hour exposure to drugs of
varying efficacy (Khan et al., 2012). Changes in ATP recorded in RLUs correlated closely with
the morphological changes observed and the time required for recovery. Based on this evidence,
one can be confident in the snapshot luciferase activity provides.
Confirmation of 2% parasitemia and 4% hematocrit as being the parameters to use can be
seen in Figure 3. The inclusion of the patient isolate 4G was to test its recent luciferase
transfection as being stable enough for use and eventually perform all screens on it in addition to
the 3D7 laboratory strain. However this did not ultimately prove to be the case so this data is
provided solely for the former purpose. It is important to note that 4G recovered a day prior to
3D7 and exhibited a much more consistent expression curve.

Effect of Gibberellic acid and Fluridone
Both GA and FLD were used at two different concentrations based on previously
performed studies and kept incubated with the previously DHA-induced dormants for 48 hours
before being washed out of the plate and replaced with media. Since FLD has inhibitory
properties, we would expect to see a delay in 3D7’s emergence from its inactive state while GA
being a phytohormone is expected to instead cause the cells to wake before the typical recovery
period (Duvalsaint, unpublished).
With both compounds, the 10 µM concentration proved to be the more influential, see
figures 4 and 5 respectively. These graphs suggest at these concentrations, GA- and FLDexposed dormant parasites saw comparably higher rates of recovery and more clearly
demonstrated luciferase stage-specific expression. In terms of activity against the DHA-induced
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dormant, when compared to a dormant with no other drugs for intervention both acted as
expected. Figure 6 clearly shows with respect to normally recovering cells, FLD produced a
distinct delay and kept parasites dormant until day 6 while GA caused cells to recrudesce by the
second day following removal of drug pressure.

MMV Malaria Box Inhibitory Screen
MMV plates were obtained approximately a month prior to use against dormant 3D7. The
mother plate of 10 mM in 100% DMSO was shared among members of the Kyle lab and an
initial dilution to 100 µM was made so that the plates could be distributed. As is described in the
methodology, a primary screen was done at 1 µM but this ultimately did not warrant any
worthwhile results. It is possible that this concentration was too low to have any pronounced
effect on the non-proliferating cells.
In any case, the 100 µM mother plates were thawed and a sample of each compound was
diluted to 2 µM instead. Since the concentration is in a 1:1 association with DMSO, a higher
concentration of MMV drug meant higher presence of DMSO at 2%. To offset any potential
interference this may cause, the control DMSO was also brought to 2% and monitored closely
for any signs indicating that the cells were not growing optimally.
Of the 400 compounds screened, about 20 exhibited activity worthy of scrutiny and of
these 3 compounds found to have activity similar to GA and can be seen in Figure 7 and Table 1.
All three caused the DHA-induced dormant parasites to wake before the characteristic recovery
period and to continue growing normally after the period would typically end. MMV665843, a
member of the drug-like set from GlaxoSmithKline had the most powerful response. As can be
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seen in Figure 8, it caused dormants to wake much sooner than the DHA average of 4 days and
sooner even than the comparatively positive control of GA.
It was difficult to distinguish what parasite sample died in exposure to the compounds
versus simply never recovered and in the future, the assay would need redesigning to
accommodate this distinction and detect for FLD-like activity.

Dormancy Screen
Under the hypothesis that dormancy is an innate response to stress from drug pressure, it
stands to reason that compounds other than artemisinin and its derivatives are capable of
triggering it. To test this notion, the MMV plates were once again diluted to 2 µM and added to
96-well plates in the same manner previously described. The primary modification was the use
of uninduced 3D7 and a 48-hour incubation period. After which, the plates were washed free of
all drug and slides were made per each well. These were then categorized morphologically for
the presence of dormancy-inducing compounds. Figure 9 shows the distribution of these
categorized stages across the 5 plates.
Morphological cues were used to identify which compounds could be inducing
dormancy, specifically by comparing its appearance to that found within published data (Grobler
et al., 2014). Of the 400 compounds screened, 32 (Appendix, Table 2) were found to have
induced what appeared to be dormancy based solely on identification through microscopy and
accompanying luciferase data for the first 48 hours. These compounds were then selected for
confirmatory testing.
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Confirmation
In order to validate the previously described results, a confirmation assay was designed to
expose ring-stage 3D7 for 48 hours, just as is in the preliminary screen and to monitor their
decline and eventual recovery over time. Two 24-well plates were used to assess 32 test
compounds, a negative control of uninfected RBCs, a positive control of unexposed iRBCs with
2% DMSO as well as DHA and pyrimethamine (PYR) serving as comparative controls of
dormancy induction.
Although the latter has been known to induce a dormant response (Nakazawa, Kanbara,
& Aikawa, 1995), it was only recently observed by members of the Kyle lab (Hott, 2015) that
PYR causes dormancy in the second cycle of development. In other words, unlike DHA, which
affects the ring stage and immediately causes an arrest of growth, PYR does not do so until
schizogony has been initiated. A few merozoites may escape this fate but then arrest as rings
upon invasion of new RBCs. Its inclusion in this assay is to determine whether the MMV
compounds induce dormancy in the first or second stage. However, this did not prove to be
valuable information as the parasite used (luciferase-transfected 3D7) by the nature of its
transfection is resistant to PYR. For that reason, any speculation regarding at which stage
dormancy occurred is just that and may not hold up if the experiment were repeated with another
such inducer, such as mefloquine.
Of the 32 compounds, 4 were found to exhibit the highest activity in inducing a dormant
response (Table 3). All compounds exhibited the expected growth curves as can be seen in
Figure 10. MMV666116, MMV665969 and MMV000787 appear to be causing growth reduction
at the 96 HR time point rather than the 48 HR, indicative of a PYR-type targeting. MMV019918
on the other hand behaves more like DHA, inducing 3D7 arrest at the 48 HR mark.
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Counting of slides concurrent to the daily plate reading ensured that there were two
different means of discerning the effect of drug on parasite growth and development (See Table
2). The former is additionally conveyed in Figure 11 as a graph of the ratio of normal parasites
(that is ring-stage, trophozoites/schizonts) out of a total of all parasites present in a respective
field. For the sake of simplicity, dead and dormant parasites were pooled together as it is difficult
to distinguish between them on a microscope slide. These values correlated nicely with the
TopCount readings. Of note is MMV019918, which seems to influence parasites to behave
similarly to DHA. Slide counts appear to detect a decline in overall healthy parasites around the
48-hour mark while the other 3 compounds saw this drop around 72 and 96 hours.
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Tables and Figures
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Figure 2. Optimization Assay: DHA. Exposed 3D7 entered dormant state within 6
hours of initial contact and maintained low metabolic rate until 96 hours post-exposure.
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Figure 3. Optimization Assay: DMSO. Exposed 3D7 serves as the positive control and
exhibits normal growth as well as stage-specific expression of luciferase enzyme.
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3D7: 1% Pct, 2% Hct
3D7: 2% Pct, 4% Hct
4G: 1% Pct, 2% Hct
4G: 2% Pct, 4% Hct
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Figure 4. Dormancy Recovery Assay: 3D7 and 4G. Both parasites were exposed to 700 nM
DHA for 6 hours, 4G was included to test its recent luciferase transfection
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Figure 5. The effect of fluridone (FLD) on DHA-induced dormant ring stages of P.
falciparum strain 3D7 was examined at 10 µM and 50 µM concentrations.
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Figure 6. The effect of gibberellic acid (GA) on DHA-induced dormant ring stages of P.
falciparum strain 3D7 was examined at 1 µM and 10 µM concentrations.
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Figure 7. Dormancy Recovery: FLD/GA versus DHA-induced dormant – comparison
between GA and FLD at 10 µM exposed to induced dormant 3D7 parasites for 48 hours
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Figure 8. MMV Screen at 2 µM Active Compounds – all three compounds are from the same
plate consisting of the drug-like set. All three hail from different libraries, that is St. Jude’s
(orange), GSK (black), and Novartis (teal) respectively.
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Table 1. MMV Hits and Provided Information.

HEOS
Compound
ID

EC50
ChEMBL
(µM)

Source

Name

MMV665806

St.
Jude

1-(2,3dimethylindol-1yl)-3-[(2methylcyclohexyl
)amino]propan-2ol

314.5

96%

0.5273

MMV665843

GNF

1,2,3,4tetrahydroacridin9-ol

199.3

82%

0.628

GSK

6-methoxy-4methylquinazolin2-amine

MMV665897

MW

Inhibition
@ 5 µM

Structure
C20H30N2O

C13H13NO

C10H11N3O
189.2

48

63%

0.927

MMV665843 Activity
MMV665843, 2 µM
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Figure 9. MMV Malaria Box Screen Most Active Compound – induction of growth in DHAinduced dormants occurred 24 hours before GA and 48 hours before 3D7 exposed to DHA alone
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Figure 10. Morphologically Categorized Results of MMV Phenotype Screen – uninduced
parasites were exposed to 2 µM of each compound of which there were 80 per provided plate for
48 hours then categorized morphologically with microscopy. Categories were unhealthy but
growing (red), distinctly normal life stages (green) and distinctly dormant or dead (blue).
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Figure 11. MMV Dormancy Screening: Active Compounds with positive control
(DHA, blue) and negative (DMSO, orange). All were exposed for 48 hours, MMV compounds at
2 µM, DHA at 700 nM and DMSO at 2%, respectively.
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Table 2. Confirmation Assay: MMV compound morphology

Compounds

48

3D7 susceptibility to MMV compounds
Time (hours)
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Figure 12. Confirmation Assay: Ratio of normal to total parasites with dead and dormants
counted together for the sake of simplicity. Parasitemia values could not be calculated as these
counts were obtained from thick smears. All were 100% normal at 0 hour, slides taken following
48 hour incubation.
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Table 3. MMV Confirmation Assay Active Compounds Provided Information

HEOS
Compound ID

MMV666116

MMV019918

MMV665969

MMV000787

Source

GSK

GSK

St. Jude

St. Jude

Name
2-[[9-[(2fluorophen
yl)methyl]2,9diazaspiro[
4.5]decan2yl]methyl]p
henol
N-[[5-(4bromo-2chlorophen
yl)furan-2yl]methyl]1piperidin4ylmethana
mine
N-[(5chloro-8hydroxyqui
nolin-7-yl)(4methylphen
yl)methyl]3methoxybe
nzamide
7-[[4-(3chlorophen
yl)piperazi
n-1yl]methyl]5(propoxym
ethyl)quino
lin-8-ol

MW

Inhibition
@ 5 µM

EC50
ChEMBL

Structure

C22H27FN2O
354.5

98

0.679

C17H20BrClN2O
383.7

96

1.505

C25H21ClN2O3
432.9

97

15

C24H28ClN3O2
425.9

54

97

1.096

DISCUSSION

Effective malaria treatment is fraught with challenges. Resistance is seemingly around
the corner for every previously superlative drug, while being deeply entrenched among those
medications that a few decades ago were vital to chemotherapy. For artemisinin, the first signs of
resistance were observed in a 2008 study of parasite clearance times following monotherapy with
artesunate. Clearance was slower among patients from the Eastern Thai-Cambodian border than
that of patients from the Thai-Myanmar border to the West (Dondorp et al., 2009). Though an
alarming fact on its own, when coupled with the proportional increase of such slow-clearing
infections from 0.6% in 2001 to 20% in 2010 with rates approaching 42% in Cambodia one must
conclude that there is cause for alarm (Flannery et al., 2013). Resistance is not only emerging but
also spreading.
Now more than ever we have need of new medicines as well as new approaches for
producing those medicines. The link to plant physiology among Plasmodium spp. is basically
irrefutable and imperatively needs further investigating. By elucidating essential biosynthetic
pathways behind such compounds like abscisic acid, we can find hitherto unknown targets as
well as broaden our knowledge of the evasion mechanisms that are at the disposal of our
protozoan foes.
Evasion is the primary response of malaria in response to the immune system’s efforts
and this tactic appears to have been extended to one of the most powerful drugs we have.
Dormancy under drug pressure is technically not treatment failure but evidence of adaptation. If
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this is a stepping-stone to something more advanced, only time and future studies will tell. In any
case, understanding is needed regarding what compounds can affect parasites in this state and
furthermore which compounds may be expected to induce such a state themselves so that their
use in monotherapy should be discouraged.
Much of what was covered and tested in this thesis has already been affirmed and
established by the work of others. Plasmodium falciparum when grown in culture to a high
parasitemia consisting exclusively of the early ring stage will enter into a non-proliferating state
when exposed to DHA, the timing of which will vary depending on the concentration used. It
will wake from this state if unperturbed typically in 96 hours. The addition of gibberellic acid
will cause activation a day before the recovery window and addition of the herbicide fluridone
will delay activation by usually another day. Together they provide evidence that isoprenoids
synthesis occurs within the protozoan and it is intrinsically tied to metabolism and growth.
Hence why these two compounds are under such investigation and why they were used as
comparable controls for the screening of potential MMV inhibitors or activators as would be the
case. The treatment implications of finding a compound to behave like GA are substantial,
though all of this work is preliminary and it would take years to properly adapt and develop a
formulation of ACT containing this extra substance to target those parasites which may have
escaped the traditional round of treatment by entering dormancy. Pulling these protozoa back
into proliferation would allow the combination drug to clear them from the blood before the
overall treatment could be called a failure.
In terms of findings, the MMV Malaria Box screen against induced-dormant parasites
was fruitful in the discovery of the quite active and most enigmatically titled MMV665843. By
another name, 1,2,3,4-tetrahydroacridin-9-0l is a quinolone-derivative that has been screened in
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over 800 different assays against a plethora of pathogens including malaria, various different
cancer cells, HIV, Trypanosoma brucei and Leishmania spp. to name a few ("PubChem
Compound Database; CID=95996," 2005). According to the supporting data given to researchers
by MMV, it is a drug-like compound provided by Novartis that meets all criteria of Lipinski’s
rule in that it has a low molecular weight, few hydrogen bond acceptors or donors, and an
ALogP of 3.29. Making it an orally active compound that should encounter few problems in the
pharmacological sense. MMV also reports that 1,2,3,4-tetrahydroacridin-9-ol had an 82%
inhibition at 5 µM of the asexual stages of 3D7 in their preliminary activity screening as well as
an EC50 of 0.628 µM.
The EC50 is the representative measure of the concentration that is 50% of the effective
dose for the particular drug for which it was calculated. In this case, 0.628 µM is the
concentration at which half of the targeted population (P. falciparum infected RBCs) would be
expected to have some response following exposure. Since this assay tested the compounds at 2
µM, a concentration 1.5x larger than its EC5o, it is not altogether surprising as to why it exhibited
a strong effect (see Fig. 8).
It should be noted that both 1,2,3,4-tetrahydroacridin-9-ol and its runner-up in terms of
activity, MMV665897 had the two lowest percent inhibition values of all of the 20-something
compounds from which they were selected. Conversely, all four of the active compounds in the
confirmatory assay regarding the induction of dormancy rather than waking from it, had
comparable percent inhibitions, which averaged at 97%. They all also had generally much larger
molecular weights and two were members of the probe-like set from St. Jude’s, meaning that
they did not meet Lipinski’s criteria. The higher inhibition could account for its dormancy
induction, 3% of parasites may be surviving the treatment by slowing their growth and then
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recrudescing a few days later. In the inhibitory screen against DHA-induced dormants, these
compounds did not exhibit activity similar to GA or FLD. Exposed parasites seemed to recover
around the same time as unexposed though to a lesser extent (Figure 12).
The same screen was not, however, successful in identifying an MMV compound with an
effect similar to that of FLD. Although there were some samples tested that seemed to show such
activity, for example MMV396665 (Fig. 13) clearly recovers 24 hours after DHA-induced
control parasites but its magnitude could be attributed to background noise so the decision was
made to leave it out of the hit compound group. The possible explanation for this outcome would
be speculative. It is possible that the FLD dilutions were made improperly or that there was some
sort of mistake made in the plating. Mycoplasma contamination could also be a culprit as it was a
frequent issue throughout the study but this would not explain why GA-exposed samples
behaved as expected. In any case, the RLU values were too low for this to be deemed significant.
Structurally the induction screen hits are incredibly diverse and complex. One is a
phenol, one an amine, another an amide and the last a quinoline derivative such as 1,2,3,4tetrahydroacridin-9-0l. Quinolines are historically among the most significant antimalarial agents
having played a central role in shaping the early years of chemotherapy. Drugs belonging to this
family are found in the medicine cabinets of tropical clinicians throughout the affected world
(Kaur et al., 2015). Due to the widespread resistance to chloroquine, the mechanism of action by
which quinolines affect plasmodium, namely by inhibiting hemozoin production so that
hemoglobin accumulates in the food vacuole and it being toxic to the parasite leads to its death,
has led to sufficient mutations in the former to reduce the efficacy of this process. The solution to
this dilemma is the synthesis of hybrids (2015) to which these two MMV drugs may also belong.
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The overall implications for the results of this thesis are that compounds can be used to
affect parasites in the currently oft-mentioned dormant state. Some, along the lines of GA and
1,2,3,4-tetrahydroacridin-9-ol may be incorporated into the combination therapy so as to ensure
as many parasites are cleared as possible. On the other hand, if the mechanism of dormancy is
one day elucidated to be similar across Plasmodium species these compounds may be used to
induce a relapse so as to permanently rid parasites from the liver in P. vivax infections.
Moreover, the MMV screen proved that compounds other than artemisinin and its derivatives are
capable of inducing dormancy despite their vast differences implying that this quiescent state is
most likely an adaptive stress-response utilized by the parasites.
Furthermore some of these compounds seem to have induced a dormant phenotype in the
second cycle of growth. Despite the lack of comparative control due to parasites being resistant
to PYR, the data does seem to indicate as much to be the case. MMV666116 and MMV665969
cause a precipitous drop in ratio of normal to total parasites at the 96-hour mark, with the decline
beginning at 72 hours (Fig. 11). This seems to correlate with the activity of PYR found by the
Kyle lab (Hott, 2015), arrest of growth occurs among the trophozoites and not rings as with
DHA, moreover the second decline at 96 HR could represent merozoites that made it through a
complete schizogony only to go dormant once inside new RBCs. Interestingly, the seemingly
2nd-cycle induced dormant state was much shorter than that of the more traditional manifestation
exhibited by MMV019918. It is possible that since these compounds follow a different
mechanism or at least target a different life stage, P. falciparum possess a different method of
avoiding them to that used in DHA. Nevertheless, one thing is certain: further study is needed to
determine the nature of this group of inhibitors, as well as the screening of larger compound
libraries for similar forms of activity.
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Figure 13. Results from Inhibitory Screen for Dormancy-inducing Compounds – DHAinduced dormants exposed to 2 µM of each compound for 48 hours did not seem to recover
similar to GA or FLD but more like DHA-only exposed parasites.
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Figure 14. MMV Screen: Fluridone (FLD)-esque compound. Sample with activity similar to
that of FLD, namely delaying recovery by 24 hours, was left out of “hits” category due to RLU
values that may not be significant. RBCs served as a negative contro
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APPENDIX
Table 4. MMV Dormancy Screen Morphology1

HEOS
Compound ID

Source

Set

MMV019406

GSK

probe

difficult to tell, could be
ring or dormant

MMV006427

GNF

drug

dormant

MMV006203

GNF

probe

some dormant, some
may be rings

Morphology

1

Stage

Morphology following incubation with each MMV Malaria Box compound at 2 µM
concentration for 48 hours. Prototypic dormant phenotype is much smaller than normal ring
stages with a shrunken nucleus, almost pyknotic in shape and a tail of condensed cytoplasm.
67

MMV665915

GNF; GSK

drug

rings, top left may be
dormant

MMV020500

GSK

drug

dormants

MMV665831

GNF; GSK

probe

one may be dormant, the
other either ring or troph

MMV001038

GNF; St.
Jude

drug

may ring or dormant

MMV006861

GNF

probe

may be ring or dormant

68

MMV000634

St. Jude

drug

dormant

MMV665928

GNF; GSK

drug

dormant

MMV665946

GSK; St.
Jude

drug

dormant

MMV665888

GSK

drug

dormant

MMV666067

GSK

drug

dormant

MMV665789

GNF

drug

may be ring or dormant

69

MMV011944

GNF; GSK

drug

dormant, some may be
rings

MMV019780

GSK

drug

dormants

MMV665906

GSK

drug

dormant

MMV666116

GSK

drug

may be ring or dormant

MMV006545

GNF

drug

dormant

MMV011795

GNF; GSK

drug

may be dormant or dead

70

MMV000848

St. Jude

drug

may be dormant or dead

MMV019918

GSK

drug

dormants

MMV000963

GNF; St.
Jude

drug

may be dormant or dead

MMV000760

St. Jude

drug

may be dormant or rings

MMV665924

GNF

probe

may be dormant or rings

MMV665971

GSK; St.
Jude

probe

dormant

71

MMV665794

GSK

probe

may be dormant or ring

MMV665969

St. Jude

probe

may be dormant or dead

MMV000787

St. Jude

probe

may be dormant or dead

MMV006764

GNF

probe

may be dormant or dead

MMV667491

Commercial
libraries

probe

dormant

MMV006522

GNF

probe

may be dormant or dead

72

